BioLineRx (BLRX) Non-Current Debt (2017 - 2026)

BioLineRx's Non-Current Debt history runs 12 years deep, the most recent figure standing at $4.5 million for Q4 2025.

• In Q4 2025, Non-Current Debt fell 50.21% year-over-year to $4.5 million; the TTM figure through Dec 2025 stood at $4.5 million (down 50.21% YoY), while the FY2025 annual figure was $4.5 million, down 50.21% from the prior year.
• Non-Current Debt for Q4 2025 stood at $4.5 million, down from $5.6 million in the prior quarter.
• The five-year high for Non-Current Debt was $18.8 million in Q2 2024, with the low at $1.0 million in Q2 2021.
• The 5-year median for Non-Current Debt is $7.9 million (2023), against an average of $8.0 million.
• The sharpest annual moves came in 2021 and 2024: Non-Current Debt sank 76.76% in 2021, then surged 121.19% in 2024.
• BioLineRx's Non-Current Debt stood at $1.0 million in 2021, then jumped by 757.46% to $8.6 million in 2022, then retreated by 23.16% to $6.6 million in 2023, then soared by 35.15% to $9.0 million in 2024, then tumbled by 50.21% to $4.5 million in 2025.
• Business Quant data shows BLRX's Non-Current Debt at $4.5 million in Q4 2025, $5.6 million in Q3 2025, and $6.7 million in Q2 2025.